Company: SXTPW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003343
Chunk: 416

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1B
Chunk 416
---
4 and July 26,
                                    2024, we issued 8,000 and 6,667 shares of common stock to Knight, respectively, upon conversion of
                                    1,291 and 1,032 shares of Series A Preferred Stock, respectively, at the conversion price detailed
                                    in Note 6 to the accompanying consolidated financial statements.

    ●
    From October 2024 to January 2025,
                                    we issued an aggregate of 579,711 shares of common stock upon the exercise of pre-funded warrants
                                    issued to investors in the September 2024 private placement.

The issuances of shares of common stock listed
above were deemed exempt from registration under Section 4(a)(2) of the Securities Act or Regulation D promulgated thereunder in that
the issuance of securities did not involve a public offering.

41

Warrants

On September 4, 2024, we issued 579,711 pre-funded
warrants, 579,711 Series A Warrants and 579,711 Series B Warrants to investors in a private offering. The Pre-Funded Warrants are exercisable
immediately upon issuance and expire when exercised in full at an exercise price of $0.005 per share. The Series A Warrants and Series
B Warrants have an exercise price of $6.90 per share and were exercisable beginning on the effective date of stockholder approval of
the issuance of the shares of Common Stock (the “Stockholder Approval”), which was received on November 6, 2024. The Series
A Warrants will expire five years from Stockholder Approval and the Series B Warrants will expire eighteen (18) months from Stockholder
Approval. H.C. Wainwright & Co., LLC acted as the exclusive placement agent in connection with the Private Placement. In connection
with the Private Placement, we issued to Wainwright the Placement Agent Warrants to purchase 43,479 shares of Common Stock. The Placement
Agent Warrants have an exercise price equal to $8.625 per share and are exercisable beginning on the effective date of the Stockholder
Approval for five years from Stockholder Approval.

In January 2025, we issued warrants to purchase
up to an aggregate of 408,621 shares of common stock at an exercise price of $3.855 per share. The January 2025 Warrants are exercisable
upon issuance and expire twenty-four months from the date of issuance. We issued to the Placement Agent